Carcinoma News and Research

RSS
Carcinoma is cancer that begins in the skin or in tissues that line or cover internal organs.
CEL-SCI initiates global Multikine Phase III trial for head and neck cancer in Russia

CEL-SCI initiates global Multikine Phase III trial for head and neck cancer in Russia

Simple lymphocyte count effectively identifies prognosis of renal cell carcinoma

Simple lymphocyte count effectively identifies prognosis of renal cell carcinoma

Pfizer's axitinib Phase 3 trial in advanced renal cell carcinoma meets primary endpoints

Pfizer's axitinib Phase 3 trial in advanced renal cell carcinoma meets primary endpoints

Common gene fault triggers a ripple of molecular signals leading to more aggressive cervical cancer

Common gene fault triggers a ripple of molecular signals leading to more aggressive cervical cancer

'Gatekeeper' protein plays a key role in skin-cancer prevention

'Gatekeeper' protein plays a key role in skin-cancer prevention

New data on personalized approaches for skin, ovarian and lung cancer to be presented at ASCO meeting

New data on personalized approaches for skin, ovarian and lung cancer to be presented at ASCO meeting

Amgen announces primary results from XGEVA Phase 3 trial in castrate-resistant prostate cancer

Amgen announces primary results from XGEVA Phase 3 trial in castrate-resistant prostate cancer

Endo and Bioniche present Urocidin Phase III trial preliminary results at 2011 AUA annual meeting

Endo and Bioniche present Urocidin Phase III trial preliminary results at 2011 AUA annual meeting

CEL-SCI initiates Multikine Phase III trial for head and neck cancer in Canada

CEL-SCI initiates Multikine Phase III trial for head and neck cancer in Canada

Over-activation of single gene promotes leukemia, but its loss causes liver cancer

Over-activation of single gene promotes leukemia, but its loss causes liver cancer

Anti-inflammatory drug celecoxib reacts with protein and induces liver cancer cells to commit suicide

Anti-inflammatory drug celecoxib reacts with protein and induces liver cancer cells to commit suicide

Roche initiates TB-403 Phase Ib/II study in glioblastoma multiforme

Roche initiates TB-403 Phase Ib/II study in glioblastoma multiforme

Merck receives FDA approval for Victrelis to treat chronic hepatitis C

Merck receives FDA approval for Victrelis to treat chronic hepatitis C

CEL-SCI initiates Multikine Phase III trial for head and neck cancer in Poland

CEL-SCI initiates Multikine Phase III trial for head and neck cancer in Poland

Genentech submits vemurafenib NDA for BRAF V600 mutation-positive metastatic melanoma

Genentech submits vemurafenib NDA for BRAF V600 mutation-positive metastatic melanoma

Plexxikon seeks vemurafenib marketing approval from FDA and EMA for melanoma treatment

Plexxikon seeks vemurafenib marketing approval from FDA and EMA for melanoma treatment

Aethlon seeks FDA meeting for re-initiation of Hemopurifier IDE study

Aethlon seeks FDA meeting for re-initiation of Hemopurifier IDE study

AGA's cutting-edge research on GI disorders to be presented at DDW 2011

AGA's cutting-edge research on GI disorders to be presented at DDW 2011

FDA approves Afinitor for treatment of progressive neuroendocrine tumors in the pancreas

FDA approves Afinitor for treatment of progressive neuroendocrine tumors in the pancreas

MMRF, APGD collaborate to develop OSI-906 for relapsed multiple myeloma treatment

MMRF, APGD collaborate to develop OSI-906 for relapsed multiple myeloma treatment

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.